TY - JOUR
TI - Amisulpride-induced hyperprolactinemia is reversible following
discontinuation
AU - Paparrigopoulos, Thomas
AU - Liappas, John
AU - Tzavellas, Elias and
AU - Mourikis, Iraklis
AU - Soldatos, Constantin
JO - Progress in Neuro-Psychopharmacology and Biological Psychiatry
PY - 2007
VL - 31
TODO - 1
SP - 92-96
PB - PERGAMON-ELSEVIER SCIENCE LTD
SN - 0278-5846
TODO - 10.1016/j.pnpbp.2006.07.006
TODO - amisulpride; antipsychotics; hyperprolactinaemia; prolactin
TODO - Background: Although amisulpride is considered to be a prolactin-raising
atypical antipsychotic drug, a limited number of studies have documented
the extent of its prolactin-elevating properties. In the present study
the effect of amisulpride on plasma levels of prolactin and the
reversibility of this untoward side effect were investigated.
Methods: 17 patients with various diagnoses received amisulpride (50-800
mg/day) or a combination of amisulpride plus other medication as needed.
Plasma prolactin was determined 26.7 +/- 9.4 days (range: 13-50 days)
after initiation of treatment and in 3 cases after a much longer period,
and 14-51 days following its withdrawal.
Results: All patients on amisulpride had hyperprolactinemia, (mean +/-
S.D. prolactin levels: 62.5 +/- 33.0 ng/ml) with females exhibiting
considerably higher prolactin levels than males. Following amisulpride
discontinuation prolactin levels were significantly (p < 000) reduced
(mean S.D. prolactin levels: 12.3 +/- 6.7 ng/ml). No significant
correlation was detected between prolactin levels and either amisulpride
dosage or duration of administration.
Conclusion: Amisulpride has a pronounced prolactin-elevating effect
which appears to be independent of dosage and duration of
administration. Hyperprolactinemia rapidly reverses following
amisulpride discontinuation. (c) 2006 Elsevier Inc. All rights reserved.
ER -